Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Finished Goods (2025)

Outlook Therapeutics (OTLK) has disclosed Finished Goods for 1 consecutive years, with $29626.0 as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods changed N/A to $29626.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $29626.0, a N/A change, with the full-year FY2025 number at $29626.0, changed N/A from a year prior.
  • Finished Goods was $29626.0 for Q3 2025 at Outlook Therapeutics, down from $377223.0 in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.3 million in Q1 2025 to a low of $29626.0 in Q3 2025.